COPD

New treatments

Winfred Manda, Stephen Israel Rennard

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Bronchodilators are central to COPD symptom management; current options include the anticholinergic ipratropium, short- and long-acting β2-agonists, and theophylline. Tiotropium which is not yet available in the United States, may become a useful addition to the armamentarium. Novel phosphodiesterase 4 inhibitors with both anti-inflammatory and bronchodilatory effects, including roflumilast, piclamilast, and cilomilast, are being investigated. Combination therapy with bronchodilators that have different mechanisms and durations of action may prove key in achieving the greatest symptom control with the fewest side effects. For example, prescribing a first-generation β2-adrenergic agonist, such as albuterol, together with an antimuscarinic agent is reasonable from the standpoints of both efficacy and safety.

Original languageEnglish (US)
Pages (from-to)953-965
Number of pages13
JournalConsultant
Volume43
Issue number8
StatePublished - Jul 1 2003

Fingerprint

Bronchodilator Agents
Chronic Obstructive Pulmonary Disease
Phosphodiesterase 4 Inhibitors
Ipratropium
Adrenergic Agonists
Muscarinic Antagonists
Albuterol
Cholinergic Antagonists
Theophylline
Anti-Inflammatory Agents
Safety
Therapeutics
Cilomilast
piclamilast
Roflumilast
Tiotropium Bromide

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Manda, W., & Rennard, S. I. (2003). COPD: New treatments. Consultant, 43(8), 953-965.

COPD : New treatments. / Manda, Winfred; Rennard, Stephen Israel.

In: Consultant, Vol. 43, No. 8, 01.07.2003, p. 953-965.

Research output: Contribution to journalReview article

Manda, W & Rennard, SI 2003, 'COPD: New treatments', Consultant, vol. 43, no. 8, pp. 953-965.
Manda W, Rennard SI. COPD: New treatments. Consultant. 2003 Jul 1;43(8):953-965.
Manda, Winfred ; Rennard, Stephen Israel. / COPD : New treatments. In: Consultant. 2003 ; Vol. 43, No. 8. pp. 953-965.
@article{c53d50ca14cf4837b18abc0b8965ad19,
title = "COPD: New treatments",
abstract = "Bronchodilators are central to COPD symptom management; current options include the anticholinergic ipratropium, short- and long-acting β2-agonists, and theophylline. Tiotropium which is not yet available in the United States, may become a useful addition to the armamentarium. Novel phosphodiesterase 4 inhibitors with both anti-inflammatory and bronchodilatory effects, including roflumilast, piclamilast, and cilomilast, are being investigated. Combination therapy with bronchodilators that have different mechanisms and durations of action may prove key in achieving the greatest symptom control with the fewest side effects. For example, prescribing a first-generation β2-adrenergic agonist, such as albuterol, together with an antimuscarinic agent is reasonable from the standpoints of both efficacy and safety.",
author = "Winfred Manda and Rennard, {Stephen Israel}",
year = "2003",
month = "7",
day = "1",
language = "English (US)",
volume = "43",
pages = "953--965",
journal = "Consultant",
issn = "0010-7069",
publisher = "Cliggott Publishing Co.",
number = "8",

}

TY - JOUR

T1 - COPD

T2 - New treatments

AU - Manda, Winfred

AU - Rennard, Stephen Israel

PY - 2003/7/1

Y1 - 2003/7/1

N2 - Bronchodilators are central to COPD symptom management; current options include the anticholinergic ipratropium, short- and long-acting β2-agonists, and theophylline. Tiotropium which is not yet available in the United States, may become a useful addition to the armamentarium. Novel phosphodiesterase 4 inhibitors with both anti-inflammatory and bronchodilatory effects, including roflumilast, piclamilast, and cilomilast, are being investigated. Combination therapy with bronchodilators that have different mechanisms and durations of action may prove key in achieving the greatest symptom control with the fewest side effects. For example, prescribing a first-generation β2-adrenergic agonist, such as albuterol, together with an antimuscarinic agent is reasonable from the standpoints of both efficacy and safety.

AB - Bronchodilators are central to COPD symptom management; current options include the anticholinergic ipratropium, short- and long-acting β2-agonists, and theophylline. Tiotropium which is not yet available in the United States, may become a useful addition to the armamentarium. Novel phosphodiesterase 4 inhibitors with both anti-inflammatory and bronchodilatory effects, including roflumilast, piclamilast, and cilomilast, are being investigated. Combination therapy with bronchodilators that have different mechanisms and durations of action may prove key in achieving the greatest symptom control with the fewest side effects. For example, prescribing a first-generation β2-adrenergic agonist, such as albuterol, together with an antimuscarinic agent is reasonable from the standpoints of both efficacy and safety.

UR - http://www.scopus.com/inward/record.url?scp=0041672173&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0041672173&partnerID=8YFLogxK

M3 - Review article

VL - 43

SP - 953

EP - 965

JO - Consultant

JF - Consultant

SN - 0010-7069

IS - 8

ER -